Efficacy

Tecentriq (Atezolizumab) Efficacy in Lung Cancer

Tecentriq (Atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody used in the treatment of lung cancer. It is particularly indicated for non-small cell lung cancer (NSCLC) and has shown efficacy in both first-line and second-line treatments. In clinical trials, Tecentriq has been shown to improve overall survival in patients with high PD-L1 expression when compared to chemotherapy alone. Specifically, in a study known as IMpower110, patients with metastatic NSCLC with high PD-L1 expression treated with Tecentriq had a median overall survival of 20.2 months compared to 13.1 months in those receiving chemotherapy.

For patients with small cell lung cancer (SCLC), Tecentriq has also demonstrated benefits. When combined with chemotherapy (carboplatin and etoposide), Tecentriq has improved overall survival in the first-line treatment of extensive-stage SCLC, as seen in the IMpower133 trial. The addition of Tecentriq to chemotherapy resulted in a median overall survival of 12.3 months versus 10.3 months for chemotherapy alone.

Rybrevant (Amivantamab-vmjw) Efficacy in Lung Cancer

Rybrevant (amivantamab-vmjw) is a bispecific antibody that targets epidermal growth factor receptor (EGFR) and MET receptor pathways. It is approved for the treatment of adult patients with NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Rybrevant's efficacy was evaluated in the CHRYSALIS study, a multicenter, non-randomized, open-label, multicohort study. Patients treated with Rybrevant showed a response rate of 40%, with a median duration of response of 11.1 months, indicating a significant clinical benefit for this patient population.

It is important to note that the efficacy of both Tecentriq and Rybrevant can vary based on individual patient factors, including biomarker status, disease stage, and prior treatments. These therapies represent significant advancements in the personalized treatment of lung cancer, but their use should be guided by a healthcare professional, taking into consideration the specific characteristics of each patient's cancer.